Actively Recruiting

Phase 4
Age: 18Years +
All Genders
NCT06971939

Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participants

Led by Neurotech Pharmaceuticals · Updated on 2026-04-29

285

Participants Needed

33

Research Sites

320 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of this global, multicenter, open-label, Phase 4 clinical extension study is to evaluate the long-term safety and efficacy of revakinagene taroretcel-lwey (Encelto™; hereinafter referred to as NT-501), in participants with macular telangiectasia type 2 (MacTel) who previously received the intraocular implant in a Phase 1, Phase 2, or Phase 3 clinical study. In addition, this study will evaluate the safety and efficacy of NT501 in participants who previously underwent the sham procedure in a Phase 3 MacTel clinical study and elect to have NT-501 implanted intraocularly in this Phase 4 study.

CONDITIONS

Official Title

Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participants

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Male or female adults who previously completed an NT-501 MacTel clinical study
  • Participants who received NT-501 implant in Phase 3 studies (Arm 1)
  • Participants who received NT-501 implant in Phase 1 or Phase 2 studies (Arm 2)
  • Participants who previously underwent the sham procedure in Phase 3 studies and choose to receive NT-501 implant (Arm 3)
  • Participants must have steady fixation in the foveal or parafoveal area and clear media for quality retinal imaging
  • Participants or their legally authorized representatives must provide written informed consent
  • Female participants of childbearing potential in Arm 3 must agree to use highly effective contraception during the study, with specific contraception requirements in France or Germany
Not Eligible

You will not qualify if you...

  • Unable to comply with study procedures or visits
  • Physical or mental conditions that increase risk or interfere with study assessments
  • Significant corneal or media opacities in the study eye to be implanted (Arm 3 only)
  • Evidence of pathologic myopia in the study eye (Arm 3 only)
  • Certain lens opacities exceeding specified grades in the study eye (Arm 3 only)
  • Lens removal within 3 months or YAG laser within 4 weeks before baseline in study eye (Arm 3 only)
  • Ocular diseases other than MacTel that may affect study outcomes (Arm 3 only)
  • Intravitreal steroid therapy within 1 year in study eye (Arm 3 only)
  • Intravitreal anti-VEGF therapy within 6 months in study eye (Arm 3 only)
  • Active exudative intraretinal or subretinal neovascularization in study eye (Arm 3 only)
  • Central serous chorioretinopathy in study eye (Arm 3 only)
  • Prior vitrectomy, penetrating keratoplasty, trabeculectomy, or trabeculoplasty in study eye (Arm 3 only)
  • History of ocular herpes virus in study eye (Arm 3 only)
  • Currently on chemotherapy
  • Pregnant or breastfeeding
  • Participation in any other clinical study of an intervention within 6 months before baseline
  • History of malignancy compromising survival during the study

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 33 locations

1

Scripps Health

La Jolla, California, United States, 92037

Not Yet Recruiting

2

Jules Stein Eye Institute/UCLA

Los Angeles, California, United States, 90085

Not Yet Recruiting

3

Stanford University School of Medicine

Palo Alto, California, United States, 94303

Not Yet Recruiting

4

Bay Area Retina Associates

Walnut Creek, California, United States, 94598

Actively Recruiting

5

Colorado Retina

Lakewood, Colorado, United States, 80228

Actively Recruiting

6

Bascom Palmer

Miami, Florida, United States, 33136

Not Yet Recruiting

7

Emory Eye Center

Atlanta, Georgia, United States, 30322

Actively Recruiting

8

Northwestern University

Chicago, Illinois, United States, 60611

Not Yet Recruiting

9

National Eye Institute

Bethesda, Maryland, United States, 20892

Not Yet Recruiting

10

Cumberland Valley Retina Consultants

Frederick, Maryland, United States, 21702

Not Yet Recruiting

11

Massachusetts Eye and Ear Infirmary, Retina Service

Boston, Massachusetts, United States, 02114

Not Yet Recruiting

12

Foundation for Vision Research

Grand Rapids, Michigan, United States, 49525

Actively Recruiting

13

Retina Consultants of Minnesota

Minneapolis, Minnesota, United States, 55435

Not Yet Recruiting

14

Envision Ocular, LLC

Bloomfield, New Jersey, United States, 07003

Actively Recruiting

15

Cincinnati Eye Institute

Cincinnati, Ohio, United States, 45242

Actively Recruiting

16

Retina Associates of Cleveland, Inc.

Cleveland, Ohio, United States, 44126

Actively Recruiting

17

Tulsa Retina Consultants

Tulsa, Oklahoma, United States, 74132

Not Yet Recruiting

18

Retina Northwest, P.C.

Portland, Oregon, United States, 97221

Not Yet Recruiting

19

Scheie Eye Institute

Philadelphia, Pennsylvania, United States, 19104

Not Yet Recruiting

20

Southeastern Retina Associates, P.C.

Knoxville, Tennessee, United States, 37922

Actively Recruiting

21

Texas Retina Associates

Dallas, Texas, United States, 75231

Not Yet Recruiting

22

Retina Center of Texas

Dallas, Texas, United States, 75251

Actively Recruiting

23

Retina Consultants of Texas

Houston, Texas, United States, 77030

Actively Recruiting

24

University of Utah John A. Moran Center

Salt Lake City, Utah, United States, 84132

Actively Recruiting

25

Cerulea

East Melbourne, Australia

Actively Recruiting

26

Lion's Eye Institute

Perth, Australia

Actively Recruiting

27

Sydney Eye Hospital

Sydney, Australia

Actively Recruiting

28

Lariboisiére Hospital

Paris, France

Not Yet Recruiting

29

University Eye Hospital Bonn

Bonn, Germany

Not Yet Recruiting

30

UNIVERSITÄTSKLINIKUM FREIBURG, Klinik für Augenheilkunde

Freiburg im Breisgau, Germany

Not Yet Recruiting

31

Augenzentrum am St. Franziskus-Hospital

Münster, Germany

Not Yet Recruiting

32

Moorefield Hospital

London, United Kingdom

Not Yet Recruiting

33

Oxford University Hospitals NHS FT

Oxford, United Kingdom

Not Yet Recruiting

Loading map...

Research Team

P

Patricia Davis

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participants | DecenTrialz